STTR—Small Business Technology Transfer—is a US government program awarding R&D grants to small businesses working with universities or federal labs.

How it works

Agencies like NIH, NSF, and DoD set topics; startups partner with research institutions on Phase I (feasibility) and Phase II (development) awards. Unlike pure SBIR, STTR requires formal collaboration with a nonprofit research partner. Awards are non-dilutive but come with reporting, IP, and sometimes commercialization obligations.

Many biotech and hard-tech startups stack STTR/SBIR with seed VC, using grants to de-risk technical milestones.

Why it matters

• Founders: Grants extend runway without cap table impact but consume time writing proposals and meeting compliance.
• Investors: Non-dilutive funding can validate science; check IP ownership between company and university.

Common mistake

Assuming grant revenue replaces venture scale-up capital. STTR phases fund R&D, not sales teams or GTM at scale.

Related ideas

SBIR, non-dilutive funding, deep tech, and university tech transfer.

When you will see it

University-linked deep-tech startups often pursue STTR Phase I awards to fund proof-of-concept work with a lab partner before seed VC.

Questions to ask

• Who owns foreground IP versus background university IP?
• What commercialization milestones attach to Phase II?
• How do grant reporting burdens affect founder time?

Practical takeaway

Treat sttr as something to define precisely in writing—not assume everyone in the room shares the same meaning. In term sheets, board decks, and LP updates, tie the concept to a concrete decision: a vote, a price input, a fund policy, or a metric formula. When definitions drift, teams misprice risk, miss leverage, or waste cycles on the wrong conversation.